Table 2.
Selected parameters before and after treatment
| Before treatment (n = 22) | After 12-weeks of treatment (n = 22) | p-value (Wilcoxon test) | |
|---|---|---|---|
| DAS28 (ESR) | 5.34 (5.18-6.08) | 3.56 (3.15-3.99) | < 0.001 |
| TEN28 | 10.0 (8.0-12.0) | 2.0 (1.0-3.0) | < 0.001 |
| SW28 | 6.0 (4.0-9.0) | 1.5 (0.0-4.0) | < 0.001 |
| VAS (mm) | 70 (60-82) | 41 (30-50) | < 0.001 |
| ESR (mm/h) | 22 (10-30) | 15 (8-25) | 0.012 |
| CRP (mg/l) | 6.80 (2.30-15.80) | 2.15 (0.10-5.50) | 0.021 |
| Leukocytes (103/µl) | 8.8 (7.2-9.9) | 7.8 (6.6-9.6) | 0.022 |
| Neutrophils (103/µl) | 5.4 (3.6-7.1) | 4.7 (3.3-5.8) | 0.006 |
| Lymphocytes (103/µl) | 2.0 (1.6-2.6) | 2.2 (1.7-3.1) | 0.079 |
| Neutrophil-to-lymphocyte ratio | 2.3 (1.8-3.8) | 1.7 (1.3-2.7) | 0.024 |
| Erythrocytes (106/µl) | 4.5 (4.3-4.7) | 4.5 (4.3-4.6) | 0.357 |
| Haemoglobin (g/dl) | 12.5 (11.9-13.6) | 12.3 (12.1-13.5) | 0.765 |
| Platelets (103/µl) | 299 (268-319) | 272 (259-309) | 0.044 |
Data presented as the median (interquartile range)
DAS28 – 28-joint disease activity score; TEN28 – the number of tender joints; SW – the number of swollen joints; VAS – subjective disease activity assessment on the visual analogue scale; ESR – erythrocyte sedimentation rate; CRP – C-reactive protein